Clinical Trials on Moderate-to-severe Alzheimer's Disease in Australia

Total 331 results

Croma-Pharma GmbH

Completed

SAVINO (Saypha® Volume LIdocaine in Nasolabial FOlds)

Moderate to Severe Nasolabial Folds

Austria
KoBioLabs
Novotech (Australia) Pty Limited

Completed

Study of Multiple Ascending Dose of KBL693 in Healthy Participants

Moderate to Severe Asthma

Australia
Cognition Therapeutics
National Institute on Aging (NIA)

Active, not recruiting

A Study to Evaluate the Safety and Efficacy of CT1812 in Subjects With Mild to Moderate Alzheimer's Disease.

Mild to Moderate Alzheimer's Disease

United States, Australia, Netherlands, Czechia, Spain
PharmatrophiX Inc.
National Institute on Aging (NIA)

Completed

Study of LM11A-31-BHS in Mild-moderate AD Patients

Mild to Moderate Alzheimer's Disease

Spain, Germany, Austria, Czechia, Sweden
Sun Pharmaceutical Industries Limited

Active, not recruiting

Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail Psoriasis

Chronic Plaque Psoriasis | Moderate to Severe Nail Psoriasis

United States, Australia
Jiangsu HengRui Medicine Co., Ltd.

Completed

Multi-Dose Study of SHR-1314 in Subjects With Moderate-to-severe Plaque Psoriasis

Moderate-to-severe Chronic Plaque Psoriasis

United States, Australia, China
Kythera Biopharmaceuticals

Completed

Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat

Moderate or Severe Submental Fullness

Australia, Canada, United Kingdom
Bausch Health Americas, Inc.

Terminated

P3 Study Brodalumab in Treatment of Moderate to Severe Plaque Psoriasis (AMAGINE-2)

Moderate to Severe Plaque Psoriasis

United States, Austria, France, Poland, Australia, Czechia, Canada, Hungary, Portugal, Spain, Netherlands
Kythera Biopharmaceuticals

Completed

Phase 1-2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat (ATX-101)

Moderate or Severe Submental Fullness

United Kingdom, Canada, Australia
Novartis Pharmaceuticals

Completed

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Nail Psoriasis (TRANSFIGURE)

Moderate to Severe Nail Psoriasis

Germany, Belgium, Spain, United States, Australia, United Kingdom, Denmark, Czechia, Greece
Debiopharm International SA

Completed

Efficacy Study of a ZT-1 Implant in Patients Suffering From Alzheimer's Disease (BRAINz)

Moderate Alzheimer's Disease

Australia, Canada, United Kingdom
AbbVie (prior sponsor, Abbott)

Completed

Open Label Continuation Study in Moderate to Severe Psoriasis

Moderate to Severe Plaque Psoriasis

United States, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Italy, Spain, Sweden, Switzerland, United Kingdom
Actinogen Medical

Recruiting

Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease (XanaMIA)

Alzheimer Disease | Dementia, Mild | Dementia Moderate

Australia
Novartis Pharmaceuticals

Completed

Study of Safety, Tolerability, and Efficacy of Secukinumab in Subjects With Moderate to Severe Palmoplantar Psoriasis (GESTURE)

Moderate to Severe Palmoplantar Psoriasis

Belgium, United States, Hungary, Russian Federation, Turkey, Australia, Israel, Netherlands, Portugal, Spain, United Kingdom, Norway, Slovakia, Canada, Finland
Novartis Pharmaceuticals

Completed

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

Moderate to Severe Plaque-type Psoriasis

Germany, United States, Belgium, Colombia, Spain, Estonia, Hungary, Japan, Lithuania, Taiwan, Australia, Korea, Republic of, Canada, Singapore, Italy, Israel, Sweden, Guatemala, United Kingdom, Argentina, France, Poland, Latvia, Iceland, Finla... and more
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Subcutaneous Secukinumab (AIN457) for Moderate to Severe Chronic Plaque-type Psoriasis Assessing Different Doses and Dose Regimens (SCULPTURE)

Moderate to Severe Plaque-type Psoriasis

United States, Czech Republic, Austria, Germany, India, Japan, Bulgaria, Singapore, Switzerland, United Kingdom, Italy, France, Poland, Slovakia, Canada, Vietnam
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE SURE)

Moderate to Severe Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, Taiwan
Novartis Pharmaceuticals

Completed

4 Year Extension Study of Efficacy and Safety of Secukinumab in Patients With Moderate to Severe Chronic Plaque-type Psoriasis

Moderate to Severe Chronic Plaque-Type Psoriasis

United States, Germany, Japan, Bulgaria, Czechia, Singapore, Switzerland, United Kingdom, Italy, France, Vietnam, Poland, Slovakia, Austria, Canada
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE RADIANT)

Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Belgium, Canada, France, Germany, Netherlands, Poland, Spain, Turkey, United Kingdom
Humanigen, Inc.

Completed

Effect of KB003 in Subjects With Asthma Inadequately Controlled by Corticosteroids (KB003-04)

Moderate-to-Severe Asthma

France, United Kingdom, United States, Australia, Poland, Ukraine
UCB Biopharma SRL

Completed

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE BRIGHT)

Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Belgium, Canada, Germany, Hungary, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Taiwan, United Kingdom
Delenex Therapeutics AG

Completed

Intra-dermal Injections of DLX105 Into Lesional Skin in Patients With Mild-to-moderate Psoriasis Vulgaris (2011-00500-15)

Mild-to-moderate Psoriasis Vulgaris

Austria, Germany
Washington University School of Medicine
Hoffmann-La Roche; National Institute on Aging (NIA); Alzheimer's Association

Terminated

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia: A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU)

Dementia | Alzheimers Disease | Alzheimers Disease, Familial

United States, France, Spain, Ireland, Canada, Australia, Puerto Rico, United Kingdom
Washington University School of Medicine
Eli Lilly and Company; Hoffmann-La Roche; Avid Radiopharmaceuticals; National Institute... and other collaborators

Completed

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. (DIAN-TU)

Dementia | Alzheimers Disease | Alzheimers Disease, Familial

United States, Canada, France, Spain, Ireland, Australia, Puerto Rico, United Kingdom
Sanofi

Completed

Study of ChimeriVax™ Dengue Tetravalent Vaccine in Adult Subjects

Dengue | Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus

Australia
Monash University
Turning Point

Completed

Brain Exercise and Addiction Trial (BEAT)

Cannabis Use Disorder, Moderate | Cannabis Use Disorder, Severe

Australia
Hoffmann-La Roche
Pfizer

Completed

A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Colitis

Moderate to Severe Ulcerative Colitis

United States, Australia, Thailand, Poland, Russian Federation, Japan, Colombia, Spain, Turkey, Romania, India, Slovakia, France, Hungary, South Africa, Belgium, Bulgaria, Germany, Italy, Mexico, Serbia, Ukraine, United Kingdom
Suzhou Connect Biopharmaceuticals, Ltd.

Completed

A Study to Assess the Efficacy and Safety of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis

Moderate-to-severe Atopic Dermatitis

United States, Australia, China, New Zealand
Washington University School of Medicine
Eli Lilly and Company; Hoffmann-La Roche; Avid Radiopharmaceuticals; National Institute... and other collaborators

Recruiting

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001 (DIAN-TU)

Dementia | Alzheimers Disease | Alzheimers Disease, Familial

United States, Canada, Italy, Argentina, Australia, Colombia, France, Ireland, Mexico, Netherlands, Puerto Rico, Spain, United Kingdom, Brazil, Japan, Germany
University of South Australia
Flinders University

Recruiting

Small Steps Towards Improving Activity and Sleep Habits to Decrease the Risk of Dementia

Dementia | Alzheimer Disease

Australia
SciNeuro

Completed

A First Time in Human Study of SNP318 as a Treatment for Neurodegenerative Diseases Including Alzheimer's Disease

Neurodegenerative Diseases | Alzheimer's Disease

Australia
Cerecin

Terminated

Tricaprilin Liquid Formulation PK Study

Alzheimer Disease

Australia
Washington University School of Medicine
National Institute on Aging (NIA); Alzheimer's Association; Eisai Inc.; Accelerating...

Recruiting

Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation (DIAN-TU) (DIAN-TU)

Dementia | Alzheimers Disease | Alzheimers Disease, Familial

United States, Canada, Italy, Argentina, Australia, Colombia, Netherlands, Puerto Rico, Spain, United Kingdom, France, Ireland, Mexico, Brazil, Japan, Germany
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia

Dengue Fever | Dengue Hemorrhagic Fever

Australia
Galderma R&D

Completed

Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis

Moderate-to-Severe Atopic Dermatitis

United States, Australia, Austria, Canada, Czechia, Germany, Korea, Republic of, Latvia, Lithuania, Netherlands, New Zealand, Poland, Spain, United Kingdom
Neuroscience Trials Australia
The Florey Institute of Neuroscience and Mental Health

Active, not recruiting

Deferiprone to Delay Dementia (The 3D Study)

Mild Cognitive Impairment | Prodromal Alzheimer's Disease | Mild Alzheimer's Disease

Australia
Takeda
Zinfandel Pharmaceuticals Inc.

Terminated

Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset (TOMMORROW)

Mild Cognitive Impairment Due to Alzheimer's Disease

United States, Germany, Switzerland, United Kingdom, Australia
AstraZeneca
MedImmune LLC

Completed

Efficacy and Safety of Benralizumab in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History (TERRANOVA)

Moderate to Very Severe Chronic Obstructive Pulmonary Disease

United States, Denmark, France, Sweden, Thailand, Vietnam, Belgium, Brazil, Peru, Philippines, Turkey, Taiwan, Argentina, Australia, Israel, Poland, Ukraine, Slovenia, Serbia, Mexico, Bulgaria, Colombia, New Zealand, Chile, Norway, Croatia
Lyndra Inc.

Completed

Study to Evaluate Safety/Duration in Stomach of Extended Release Capsules Containing Memantine Hydrochloride in Healthy Adults

Healthy | Alzheimer Disease | Gastric Retention

Australia
Novartis Pharmaceuticals

Completed

A Dose Finding Study of AEB071 Assessing Psoriasis Area and Severity Index in Patients With Plaque Psoriasis

Moderate and Severe Plaque Psoriasis

United States, Argentina, Germany, Belgium, Italy, United Kingdom, Turkey, Guatemala, Australia
Actinogen Medical
Avance Clinical

Completed

A Double-Blind, Placebo-Controlled, Dose Ranging Study of Xanamem® in Healthy Elderly Volunteers (XanaMIA-DR)

Mild Cognitive Impairment | Alzheimer's Disease

Australia
AstraZeneca
MedImmune LLC

Completed

Benralizumab Efficacy in Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) With Exacerbation History (GALATHEA)

Moderate to Very Severe Chronic Obstructive Pulmonary Disease

United States, Canada, Germany, Italy, Netherlands, Spain, United Kingdom, Poland, Japan, Austria, Korea, Republic of, Russian Federation, South Africa, Czechia, Hungary, Romania, Switzerland
Nektar Therapeutics

Recruiting

A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis (REZOLVE-AD)

Moderate to Severe Atopic Dermatitis

United States, Australia, Canada
Galderma R&D

Active, not recruiting

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Moderate-to-Severe Atopic Dermatitis

United States, Australia, Austria, Belgium, Bulgaria, Canada, Czechia, Estonia, France, Georgia, Germany, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Netherlands, New Zealand, Poland, Singapore, Spain, United Kingdom
Washington University School of Medicine
Hoffmann-La Roche; Genentech, Inc.; National Institute on Aging (NIA); Alzheimer...

Suspended

A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation (DIAN-TU)

Dementia | Alzheimers Disease | Alzheimers Disease, Familial

United States, Canada, Italy, France, Spain, Ireland, Argentina, Australia, Colombia, Germany, Mexico, Netherlands, Puerto Rico, United Kingdom
Takeda

Terminated

AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer Disease

Mild Cognitive Impairment Due to Alzheimer's Disease

United States, Australia, United Kingdom, Switzerland
Inventage Lab., Inc.

Recruiting

A Clinical Trial to Access Pharmacokinetic Profiles and Safety of IVL3003.

Alzheimer Disease

Australia
Biogen

Recruiting

A Study to Learn About the Safety of BIIB080 and Whether it Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age (CELIA)

Mild Cognitive Impairment Due to Alzheimer's Disease | Alzheimer's Disease Dementia

Belgium, United States, Australia, Italy, Spain, Denmark, United Kingdom, Czechia, France, Poland, Switzerland, Germany, Canada, Japan, Finland, Netherlands, Sweden
UCB Biopharma SRL

Completed

A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis (BE READY)

Psoriatic Arthritis | Moderate to Severe Chronic Plaque Psoriasis | Chronic Plaque Psoriasis

United States, Australia, Canada, Germany, Hungary, Korea, Republic of, Poland, Russian Federation, United Kingdom
Hoffmann-La Roche

Terminated

A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD) (SKYLINE)

Alzheimers Disease

United States, United Kingdom, Korea, Republic of, Poland, Canada, Australia, Argentina, Spain, Sweden, Italy

Clinical Trials on Moderate-to-severe Alzheimer's Disease in Australia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Spain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations